REJUVXL
Live / Applied — First extension granted (statement of use) (as of 23 Feb 2026)
What this means for you
Not registered yet, but its 20 Sept 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98189228
- Mark type
- Stylized text
- Filed
- 20 Sept 2023
- Published for opposition
- 01 Jul 2025
- Attorney of record
- Michael R. Graif
Goods and services
- Class 001 — Chemicals: Cell therapy preparation in the nature of cells for development use, other than for medical or veterinary purposes
- Class 005 — Pharmaceuticals: Cell therapy preparation in the nature of cells for medical and clinical use; cell therapy preparation in the nature of cryopreserved cells for medical and clinical use; cell therapy preparation in the nature of cell suspension being living cells for medical and clinical use; cell therapy preparation in the nature of pharmaceutical preparations, namely, living cells for injection for medical and clinical use for treating chronic, inflammatory, or immune-mediated conditions; cell therapy preparation in the nature of pharmaceutical preparations, namely, living cells, for infusion for medical and clinical use for treating kidney disease; cell therapy preparation in the nature of pharmaceutical preparations, namely, living cells for treating chronic diseases such as chronic kidney disease, inflammatory diseases such as lung disease, immune-mediated conditions such as autoimmune disease or graft-versus-host disease, degenerative diseases such as neurodegenerative diseases; cell therapy preparation in the nature of cell clusters being living cells clusters for medical and clinical use; cell therapy preparation in the nature of tissue being biological tissue cultures for medical and clinical use; therapeutic preparation in the nature of cell derivatives being biological materials derived from cells, namely extracellular vesicles, secretome, conditioned media, soluble factors, membrane fragments, or extracellular matrix for medical and clinical use; cell therapy preparation in the nature of pharmaceutical preparations comprised of molecules for combination with cell therapy for medical and clinical use for treating kidney disease; cell therapy preparation in the nature of pharmaceutical preparations comprised of molecules for combination with cells for medical and clinical use for treating chronic, inflammatory, or immune-mediated conditions; cell therapy preparation in the nature of pharmaceutical preparations comprised of supramolecular complexes in combination with cells for medical and clinical use for treating chronic, inflammatory, or immune-mediated conditions; cell therapy preparation of cell components being mitochondria or vesicles for medical and clinical use
- Class 042 — Scientific and technological services: Medical and scientific research and development in the field of cell therapy, regenerative medicine and healthspan medicine; cell therapy preparation in the nature of testing for research, development, engineering and testing services in the fields of immunopharmaceuticals, immunomodulators
- Class 044 — Medical, beauty and agricultural services: Medical services; medical treatment using cultured cells; medical treatment of Chronic Kidney Disease using living cells; medical treatment, namely, injection of living cells for the treatment of chronic, inflammatory, or immune-mediated conditions; medical treatment, namely, infusion of living cells for the treatment of chronic, inflammatory, or immune-mediated conditions; medical treatment, namely, injection, infusion, and implantation of living cells in combination with induction and maintenance treatment with vitamins, protective molecules, and pharmacological agents for the treatment of Chronic Kidney Disease
Owner
- AION Healthspan, Inc., Miami, FL, US
- AION Healthspan, Inc., Miami, FL, US
Prosecution history
- 24 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Feb 2026 — SOU EXTENSION 1 GRANTED
- 23 Feb 2026 — SOU EXTENSION 1 FILED
- 23 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 26 Aug 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 31 Jul 2025 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 31 Jul 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 31 Jul 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 31 Jul 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 01 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 01 Jul 2025 — PUBLISHED FOR OPPOSITION
- 25 Jun 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 29 May 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 28 May 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 28 May 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE